Get access

Adenoid Cystic Carcinoma of the Nasopharynx: 27-Year Experience

Authors

  • Tian-Run Liu MD,

    1. State Key Laboratory of Oncology, Southern China, Guangzhou, Guangdong, People's Republic of China
    2. Departments of Head and Neck, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    Search for more papers by this author
  • An-Kui Yang MD,

    1. State Key Laboratory of Oncology, Southern China, Guangzhou, Guangdong, People's Republic of China
    2. Departments of Head and Neck, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    Search for more papers by this author
  • Xiang Guo MD,

    1. State Key Laboratory of Oncology, Southern China, Guangzhou, Guangdong, People's Republic of China
    2. Department of Nasopharynx, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    Search for more papers by this author
  • Qui-Li Li MD,

    1. State Key Laboratory of Oncology, Southern China, Guangzhou, Guangdong, People's Republic of China
    2. Departments of Head and Neck, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    Search for more papers by this author
  • Ming Song MD,

    1. State Key Laboratory of Oncology, Southern China, Guangzhou, Guangdong, People's Republic of China
    2. Departments of Head and Neck, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    Search for more papers by this author
  • Jie-Hua He MD,

    1. Department of Pathology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    Search for more papers by this author
  • Yan-Hong Wang MD,

    1. State Key Laboratory of Oncology, Southern China, Guangzhou, Guangdong, People's Republic of China
    2. Departments of Head and Neck, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    Search for more papers by this author
  • Zhu-Ming Guo MD,

    1. State Key Laboratory of Oncology, Southern China, Guangzhou, Guangdong, People's Republic of China
    2. Departments of Head and Neck, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    Search for more papers by this author
  • Quan Zhang MD,

    1. State Key Laboratory of Oncology, Southern China, Guangzhou, Guangdong, People's Republic of China
    2. Departments of Head and Neck, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    Search for more papers by this author
  • Wen-Quan Chen MD,

    Corresponding author
    1. State Key Laboratory of Oncology, Southern China, Guangzhou, Guangdong, People's Republic of China
    2. Departments of Head and Neck, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    • Fu-Jin Chen, MD, Department of Head and Neck, Cancer Center of Sun Yat-sen University, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People's Republic of China
    Search for more papers by this author
  • Fu-Jin Chen MD

    Corresponding author
    1. State Key Laboratory of Oncology, Southern China, Guangzhou, Guangdong, People's Republic of China
    2. Departments of Head and Neck, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
    • Fu-Jin Chen, MD, Department of Head and Neck, Cancer Center of Sun Yat-sen University, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People's Republic of China
    Search for more papers by this author

Abstract

Objective/Hypothesis: Nasopharyngeal adenoid cystic carcinoma (NACC) is a rare malignancy with special biological features. Clear consensus is not available regarding the clinical characters, management approaches, and prognostic factors. We presented one institution's experience with this tumor and the outcomes of treatment.

Study Design: Retrospective clinical analysis.

Methods: The medical records of 26 patients with NACC at one institution between 1976 and 2003 were reviewed. Patient records were analyzed for clinical characteristics, management approaches, and outcomes. Survival analysis was performed by Kaplan-Meier method, comparison between groups was performed using log-rank test.

Results: The lymphatic metastases rate and distant metastases rate were 3.8% and 26.9%, respectively. Epstein-Barr virus did not have a close relationship to the incidence of NACC. The 5-year disease free survival rate and overall survival rate (OS) for all patients were 30.3% and 54.8%, respectively. In the stage I, II and III patients, the 5-year OS were 87.5% and 49.4%, respectively in patients treated mainly by combined surgical treatment with radiotherapy and those treated mainly by radiotherapy. Cranial nerves invasion, advanced stage and nonsurgical treatment indicated a significant worse OS, whereas combined surgical treatment was an independent factor affecting disease free survival rate and OS.

Conclusions: NACC is a malignancy with low rate of lymphatic metastases. NACC should be treated by combined surgical operation and radiotherapy. Cranial nerves invasion, stage and treatment approach might be important factors affecting the prognosis of the patients with NACC.

Ancillary